COVID Intel - by Dr.William Makis

Share this post

IVERMECTIN - powerful repurposed agent against Acute Myeloid Leukemia (AML) and other Leukemias.

makismd.substack.com

IVERMECTIN - powerful repurposed agent against Acute Myeloid Leukemia (AML) and other Leukemias.

Dr. William Makis MD
Aug 08, 2024
∙ Paid
119
Share this post

IVERMECTIN - powerful repurposed agent against Acute Myeloid Leukemia (AML) and other Leukemias.

makismd.substack.com
12
Share
Figure 1. A screen of off-patent drugs identifies the antiparasitic agent, ivermectin, that reduces viability of leukemia cells. (A) OCI-AML2 cells were treated with aliquots of a small chemical library (n = 100) focused on antimicrobials and metabolic regulators. Seventy-two hours after incubation, cell growth and viability were measured by the MTS assay. Data represent the percentage of viable OCI-AML2 cells treated with the compounds (6μM) sorted in order of increasing activity. (B) Leukemia cell lines were treated with increasing concentrations of ivermectin. Seventy-two hours after incubation, cell growth and viability were measured by the MTS assay. Data represent the mean EC50 and 95% CI from 3 independent experiments. (C) Primary normal hematopoietic cells (PBSC; n = 3), primary AML patient samples (AML; n = 3), and U937 leukemia cells were treated with increasing concentrations of ivermectin for 48 hours. After incubation, cell viability was measured by annexin V and PI staining. Data represent the mean ± SD percent viable cells from experiments performed in triplicate. (D) Primary AML cell samples (AML; n = 6) and normal hematopoietic peripheral blood stem cell samples (PBSC; n = 3) were treated with ivermectin (6μM) for 24 hours and then plated in a methylcellulose colony forming assay. Seven (AML) or 14 days (PBSCs) days after plating, the number of colonies was counted. Data represent the mean ± SD percent colony formation compared with control treated cells.

Keep reading with a 7-day free trial

Subscribe to COVID Intel - by Dr.William Makis to keep reading this post and get 7 days of free access to the full post archives.

Already a paid subscriber? Sign in
© 2024 Dr. William Makis MD
Privacy ∙ Terms ∙ Collection notice
Start WritingGet the app
Substack is the home for great culture
Share